Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure

Zhengye Biotechnology (Nasdaq: ZYBT) implemented a dual-class share structure effective April 7, 2026, following shareholder approval on March 24, 2026.

Rhea-AI Summary

Zhengye Biotechnology (Nasdaq: ZYBT) implemented a dual-class share structure effective April 7, 2026, following shareholder approval on March 24, 2026.

The authorized capital was reclassified to 2,000,000,000 ordinary shares (1,900,000,000 Class A; 100,000,000 Class B). Class A carries one vote; Class B carries twenty votes and is convertible into Class A at holder option. Amended governance documents were filed and are effective.

Positive

• Class A shares continue trading under ticker ZYBT
• Adopted amended articles and memorandum now filed and effective
• Class B conversion gives holders optional liquidity via conversion to Class A

Negative

• Class B shares carry 20 votes per share, concentrating voting power
• Class A shares are non-convertible into Class B, limiting vote mobility
• Authorized share capital reclassified to 2,000,000,000 shares, changing capital structure

Argus Apr 6 session

+1.23% close to close Open Argus

Details

News Market Reaction – ZYBT

On Apr 6, the day this news came out, ZYBT closed 1.23% above the previous close.

Data tracked by StockTitan Argus for the Apr 6 session.

Market Context

This announcement details a shift to a dual-class share structure, authorizing 2,000,000,000 ordinar...

Analysis

This announcement details a shift to a dual-class share structure, authorizing 2,000,000,000 ordinary shares split between Class A and high-vote Class B shares, each at US$0.000025 par value. Class B carries 20 votes and can convert 1:1 into Class A. Together with prior disclosures on governance and regulatory risk, investors may focus on how this voting framework, board composition, and future filings shape long-term control and oversight.

Key Figures

Authorized share capital: US$50,000 Authorized ordinary shares: 2,000,000,000 shares Class A authorized: 1,900,000,000 shares +5 more

Authorized share capital

US$50,000

Total authorized share capital after dual-class reorganization

Authorized ordinary shares

2,000,000,000 shares

Total ordinary shares of par value US$0.000025 each

Class A authorized

1,900,000,000 shares

Class A ordinary shares of par value US$0.000025 each

Class B authorized

100,000,000 shares

Class B ordinary shares of par value US$0.000025 each

Par value

US$0.000025 per share

Par value for both Class A and Class B ordinary shares

Class A voting rights

1 vote per share

Voting power for each Class A ordinary share

Class B voting rights

20 votes per share

Voting power for each Class B ordinary share

Effective date

April 7, 2026

Dual-class share structure and Class A trading effective date

Historical Context

1 past event · Latest: Feb 10

1 event

1. Feb 10

   Chairman’s letter update

   24h Move

   -2.9%

   Outlined 2025 milestones and 2026 strategic priorities across R&D and commercialization.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

dual-class share structure, class a ordinary shares, class b ordinary shares, cusip, +2 more

6 terms

dual-class share structure financial

"today announced the implementation of a dual-class share structure, effective April 7, 2026."

A dual-class share structure is when a company issues two (or more) types of stock that give different voting power: one class typicaly gives founders or insiders more votes per share while the other class, sold to public investors, has little or no voting rights. For investors this matters because it concentrates control in a small group—like a family owning a house with most of the keys—so minority shareholders may have less influence over strategy, governance and risk, which can affect long-term value and accountability.

class a ordinary shares financial

"two classes of ordinary shares, designated as Class A and Class B."

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

class b ordinary shares financial

"two classes of ordinary shares, designated as Class A and Class B."

Class B ordinary shares are a type of ownership stake in a company that typically come with different voting rights or privileges compared to other share classes. For investors, they represent a way to hold part of the company’s value and influence its decisions, often with fewer voting rights than Class A shares. Understanding these shares helps investors assess their level of control and potential returns within a company.

cusip financial

"While the CUSIP number will remain the same, the CUSIP description will be updated"

A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.

View in glossary

par value financial

"ordinary shares of a par value of US$0.000025 each, comprising (i) 1,900,000,000"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

memorandum and articles of association regulatory

"Zhengye has adopted amended and restated memorandum and articles of association,"

Memorandum and articles of association are the founding legal documents of a company: the memorandum sets out the company’s basic purpose and scope, while the articles act as its internal rulebook detailing how the company is run, who has what powers, and how decisions are made. For investors these documents matter because they define ownership rights, voting rules, limits on activities, and procedures for major changes—like a contract and rulebook that determine how their investment can be used and protected.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Jilin, China, April 06, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced the implementation of a dual-class share structure, effective April 7, 2026.

At the annual general meeting of shareholders held on March 24, 2026, the Company’s shareholders approved the introduction of two classes of ordinary shares, designated as Class A and Class B. The Company’s Class A ordinary shares are expected to begin trading on the Nasdaq Capital Market at the open of business on April 7, 2026, continuing under the ticker symbol “ZYBT.” While the CUSIP number will remain the same, the CUSIP description will be updated to reflect the new designation as Class A ordinary shares.

Pursuant to the dual-class share structure, the Company’s authorized share capital of US$50,000 is re-designated and re-classified into 2,000,000,000 ordinary shares of a par value of US$0.000025 each, comprising (i) 1,900,000,000 Class A ordinary shares of a par value of US$0.000025 each, and (ii) 100,000,000 Class B ordinary shares of a par value of US$0.000025 each. Each Class A ordinary share is entitled to one (1) vote, and each Class B ordinary share is entitled to twenty (20) votes on all matters subject to vote at general meetings of the Company. Each Class B ordinary share is convertible into one (1) Class A ordinary share at any time at the option of the holder thereof, whereas in no event shall Class A ordinary share be convertible into Class B ordinary share.

To reflect the share capital reorganization, Zhengye has adopted amended and restated memorandum and articles of association, which have been duly filed and are now effective.

About Zhengye Biotechnology Holding Limited

Through Jilin Zhengye Biological Products Co., Ltd., the Company’s operating entity based in Jilin, China, Zhengye Biotechnology Holding Limited focuses on the research, development, manufacturing, and sales of veterinary vaccines, with an emphasis on vaccines for livestock. For over 20 years, the operating entity has been committed to enhancing the health of animals. The operating entity has 50 veterinary vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs. The operating entity’s products are available in 28 provincial regions across China and are exported overseas to Vietnam, Pakistan, and Egypt. The operating entity has three GMP veterinary vaccine production floors (including 13 GMP vaccine production lines), one quality examination center, and one animal facility for vaccine development. The operating entity has 49 employees who have over a decade of tenure and experience in the veterinary vaccine industry. For more information, please visit the Company’s website: http://ir.jlzybio.com.

Forward-Looking Statements

This announcement contains statements that may constitute “forward-looking” statements which are made pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions in this announcement. Statements that are not historical facts, including statements about the Company’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the United States Securities and Exchange Commission.

For more information, please contact:

Zhengye Biotechnology Holding Limited
Investor Relations Department
Email: ir@jlzybio.com

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What change did Zhengye (ZYBT) announce about its share structure on April 6, 2026?

Zhengye adopted a dual-class share structure effective April 7, 2026. According to the company, shareholders approved creating Class A and Class B shares at the March 24, 2026 meeting, with amended governance documents filed and effective.

How many votes does each Zhengye (ZYBT) Class B share carry after the reclassification?

Each Class B ordinary share carries twenty (20) votes per share. According to the company, Class A carries one vote and Class B is convertible into Class A at the holder's option.

How many total shares were authorized after Zhengye's (ZYBT) reclassification on April 7, 2026?

The company reclassified authorized capital into 2,000,000,000 ordinary shares. According to the company, that comprises 1,900,000,000 Class A and 100,000,000 Class B ordinary shares.

Will Zhengye (ZYBT) ticker or CUSIP change after the dual-class implementation?

ZYBT will continue trading under the same ticker; the CUSIP number remains unchanged. According to the company, only the CUSIP description will be updated to reflect Class A designation.

Can holders convert between Zhengye (ZYBT) Class A and Class B shares after the change?

Class B shares are convertible into one Class A share at the holder's option, but Class A shares are not convertible into Class B. According to the company, conversion is one-way from Class B to Class A.